Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 517 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sepsis Clear all

Conditions: Septic Shock
Interventions: Angiotensin II, Norepinephrine; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Winston-Salem, North Carolina

Conditions: Severe Sepsis
Interventions: Nivolumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Sacramento, California • Colorado Springs, Colorado • Denver, Colorado + 12 more

Conditions: Acute Kidney Injury Due to Sepsis
Interventions: Recombinant human alkaline phosphatase, Placebo; Biological · Other
Lead sponsor: AM-Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 16
States / cities: Tucson, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more

Conditions: Sepsis Syndrome, Sepsis, Severe Sepsis, Septic Shock, Infection
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 1,304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Systemic Inflammatory Response Syndrome
Interventions: miRNA in Sepsis; Procedure
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 1 Year to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: Bacterial Infections
Interventions: Not listed
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 85 Years
Enrollment: 77 participants
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Catheter-Related Infections
Interventions: Ethanol lock, Heparin lock; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Septic Shock
Interventions: MR imaging; Diagnostic Test
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 3 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Lymphoma, Blood Disorders, Solid Tumors
Interventions: Ethanol lock therapy (ELT); Drug
Lead sponsor: Children's Hospital of Michigan; Other
Eligibility: 6 Months to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Disability, Physical Activity, Aging, Critical Illness
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sepsis, Septic Shock, Metabolic Disturbance
Interventions: vitamin C, vitamin B1, hydrocortisone, Normal saline; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Boston, Massachusetts • Cambridge, Massachusetts + 6 more

Conditions: Central Line Associated Blood Stream Infections (CLABSI)
Interventions: (taurolidine and heparin) catheter lock solution, Heparin; Drug
Lead sponsor: CorMedix Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Doral, Florida + 14 more

Conditions: Sepsis
Interventions: Blood sampling; Device
Lead sponsor: Abionic SA; Industry
Eligibility: 18 Years and older
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Chicago, Illinois • Lexington, Kentucky • Toledo, Ohio + 1 more

Conditions: Severe Trauma
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions: ALT-836, Placebo; Drug
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 20
States / cities: Los Angeles, California • Sacramento, California • Stanford, California + 15 more

Conditions: Sepsis
Interventions: Drotrecogin alfa (activated); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 152
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 149 more

Conditions: Sepsis
Interventions: Doripenem; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sepsis, Severe, Septic Shock
Interventions: Ascorbic Acid, Thiamine, Hydrocortisone, Sodium Chloride 0.9%; Drug
Lead sponsor: Community Medical Center, Toms River, NJ; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Lakewood, New Jersey • Toms River, New Jersey

Conditions: Sepsis, Acute Respiratory Distress Syndrome (ARDS)
Interventions: Artifical Intelligence-Generated Treatment Recommendations; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pneumonia, Sepsis
Interventions: Recombinant Chimeric Monoclonal Antibody; Drug
Lead sponsor: ICOS Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Bothell, Washington

Conditions: Clinical Sepsis
Interventions: Sepsis Transition And Recovery (STAR), Usual care; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Premature Birth, Sepsis
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 3 Days
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sepsis, Severe Sepsis
Interventions: Intravenous fluid; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 5
States / cities: Newark, Delaware • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Atrophy, Sepsis, Weakness
Interventions: Not listed
Lead sponsor: Gregory A. Schmidt; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.

(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

Mitochondrial DNA as a Biomarker of Sepsis Severity

Modulation of Molecular Fingerprinting in Pediatric Sepsis

An Evaluation of a Antimicrobial Stewardship Recommendation Bundle for Staphylococcus Aureus Bloodstream Infections

Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections

Neuroimaging and Neuromonitoring in Critically Ill Children With Sepsis

Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection

Actigraphy to MEasuRe Intensive Care Unit Activity

Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial

Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis

Immune-cell Membrane Trafficking

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients

Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.

Evaluating Artificial Intelligence-Based Clinical Decision Support for Sepsis and ARDS

A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

Improving Morbidity During Post-Acute Care Transitions for Sepsis

Characteristics of Cord Blood Immunologic Parameters of Infants <32 Weeks Gestation

Preemptive Resuscitation for Eradication of Septic Shock

Muscle Atrophy in Sepsis